Prothena Q3 2024 Earnings Report

Prothena EPS Results

• Actual EPS: -$1.10
• Consensus EPS: -$1.18
• Beat/Miss: Beat by +$0.08
• One Year Ago EPS: $0.38

Prothena Revenue Results

• Actual Revenue: $0.97 million
• Expected Revenue: $1.22 million
• Beat/Miss: Missed by -$250.00 thousand
• YoY Revenue Growth: -98.90%

Prothena Announcement Details

• Quarter: Q3 2024
• Date: 11/12/2024
• Time: After Market Closes

Prothena (NASDAQ:PRTA), a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.